| Literature DB >> 35998927 |
Anna Chu1, Baiju R Shah1, Mohammed Rashid1, Gillian L Booth1, Ghazal S Fazli1, Karen Tu1, Louise Y Sun1, Husam Abdel-Qadir1, Catherine H Yu1, Sheojung Shin1, Kim A Connelly1, Sheldon Tobe1, Peter P Liu1, Douglas S Lee2.
Abstract
BACKGROUND: Early identification of people with diabetes or prediabetes enables greater opportunities for glycemic control and management strategies to prevent related complications. To identify gaps in screening for these conditions, we examined population trends in receipt of timely glucose testing overall and in specific clinical subgroups.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35998927 PMCID: PMC9402266 DOI: 10.9778/cmajo.20210195
Source DB: PubMed Journal: CMAJ Open ISSN: 2291-0026
Figure 1:Up-to-date glucose testing rates among adults aged 40 years or older in Ontario, by age (years), 2010–2017. “Up to date” is defined as at least 1 glycosylated hemoglobin, plasma or serum glucose or oral glucose tolerance test in the previous 3 years, and excludes people who received a diabetes diagnosis before the study period.
Figure 2:Up-to-date glucose testing rates among (A) men and (B) women aged 40 years and older in Ontario, by ethnicity, 2010–2017. “Up to date” is defined as at least 1 glycosylated hemoglobin, plasma or serum glucose or oral glucose tolerance test in the previous 3 years, and excludes people who received a diabetes diagnosis before the study period. Groups are displayed in order of increasing overall rates of testing in 2017.
Characteristics of being up to date or not up to date with glucose testing among people aged 40 years and older in Ontario, 2017
| Characteristic | No. (%) | Std. difference | |
|---|---|---|---|
| Yes | No | ||
| Sex | 0.22 | ||
| Men | 1 891 174 (44.3) | 869 149 (55.5) | |
| Women | 2 373 074 (55.7) | 697 858 (44.5) | |
| Age, yr | |||
| Mean ± SD | 58.1 ± 12.0 | 53.5 ± 11.3 | 0.39 |
| Median (IQR) | 56 (49–66) | 51 (45–59) | 0.42 |
| Community size | 0.03 | ||
| Rural | 467 345 (11.0) | 183 529 (11.8) | |
| Urban | 3 787 951 (89.0) | 1 370 074 (88.2) | |
| Neighbourhood income quintile | |||
| 1 (highest) | 744 427 (17.5) | 333 079 (21.5) | 0.1 |
| 2 | 823 090 (19.4) | 311 113 (20.0) | 0.02 |
| 3 | 853 497 (20.1) | 294 214 (18.9) | 0.03 |
| 4 | 873 713 (20.5) | 288 753 (18.6) | 0.05 |
| 5 (lowest) | 959 188 (22.6) | 325 952 (21.0) | 0.04 |
| Surname-based ethnicity | |||
| Chinese | 233 458 (5.5) | 111 486 (7.1) | 0.07 |
| South Asian | 126 223 (3.0) | 39 755 (2.5) | 0.04 |
| Other | 3 904 567 (91.6) | 1 415 701 (90.4) | 0.03 |
| Rostered to a primary care physician | |||
| Yes | 3 566 023 (83.6) | 918 832 (58.6) | 0.57 |
| Virtual | 575 762 (13.5) | 219 041 (14.0) | 0.01 |
| No | 122 463 (2.9) | 429 134 (27.4) | 0.73 |
| No. of visits to a family physician (2014–2016) | |||
| Mean ± SD | 11.7 ± 11.8 | 4.8 ± 8.9 | 0.66 |
| Median (IQR) | 9 (4–15) | 2 (0–6) | 1.03 |
| No. of visits to a family physician (2014–2016): categorized | |||
| None | 200 418 (4.7) | 561 869 (35.9) | 0.84 |
| 1–3 | 626 772 (14.7) | 382 643 (24.4) | 0.25 |
| 4–9 | 1 462 081 (34.3) | 386 404 (24.7) | 0.21 |
| 10+ | 1 974 977 (46.3) | 236 091 (15.1) | 0.72 |
| Hypertension | 1 593 337 (37.4) | 247 523 (15.8) | 0.50 |
| History of hyperlipidemia | 218 957 (5.1) | 13 479 (0.9) | 0.25 |
| Any history of cardiovascular disease | 208 689 (4.9) | 30 320 (1.9) | 0.16 |
Note: IQR = interquartile range, SD = standard deviation.
Unless otherwise specified.
p value for differences all < 0.001.
Data for community size and neighbourhood income quintile are missing for 22 356 and 24 229 people, respectively.
With virtual rostering, a patient is not formally on a physician’s roster, but received most of their primary care from a specific physician in 2015/16.
Defined as any previous hospital admission for myocardial infarction, stroke, heart failure, percutaneous coronary intervention or coronary artery bypass graft surgery.
Figure 3:Annual glucose testing rates among high-risk populations in Ontario 2008–2017: (A) people with hypertension, (B) people with hyperlipidemia and (C) people with cardiovascular disease. “Glucose testing” is defined as at least 1 glycosylated hemoglobin, plasma or serum glucose or oral glucose tolerance test and excludes people who received a diabetes diagnosis before the study year or were admitted to hospital during the study year. “Cardiovascular disease” is defined as a history of hospital admission for myocardial infraction, stroke or heart failure, or previous percutaneous coronary intervention or coronary artery bypass graft surgery.